Dosing and Administration

WockAIR® maintenance therapy in asthma and COPD¹

Each dose contains two compounds for the treatment of asthma or COPD¹

WockAIR® is a combination inhaler (a preventer and long-acting reliever in a single inhaler), and contains two molecules: budesonide and formoterol fumarate dihydrate which are used to treat asthma in adults and adolescents aged 12-17 years, and Chronic Obstructive Pulmonary Disease (COPD) in adults aged 18 and over¹

Budesonide works by reducing and preventing swelling and infla­mmation in the lungs and formoterol fumarate dihydrate works by relaxing the muscles in the airway.

Maintenance Therapy Chart

For asthma the required dose of each component of WockAIR® is individual and should be adjusted to the severity of the disease. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. WockAIR® is not intended for the initial management of asthma and is not recommended for children younger than 12 years.

Maintenance and reliever therapy (MART) in asthma¹

With MART in asthma, patients take a daily maintenance dose of WockAIR® and in addition take WockAIR® as needed in response to symptoms. Meaning both treatments in one handy device.

MART administration applies to the 160/4.5 inhaler only.

Patients should be advised always to have WockAIR® available for rescue use.

No more than 6 inhalations should be taken on any single occasion. A total daily dose of up to 12 inhalations could be used for a limited period. Patients using more than 8 inhalations daily should be strongly recommended to seek medical advice. They should be reassessed and their maintenance therapy should be reconsidered.¹

Adverse events should be reported. Reporting forms and information can be found at:

Adverse events should also be reported to Wockhardt UK. Please contact us or email us at


1. WockAIR® Summary of Product Characteristics